International Journal of Hematology

, 81:433

Rituximab Provided Long-Term Remission in a Patient with Refractory Relapsing Thrombotic Thrombocytopenic Purpura

Authors

    • Department of Internal MedicineToyonaka Municipal Hospital
  • Masanori Matsumoto
    • Department of Blood Transfusion MedicineNara Medical University
  • Yasushi Ohtani
    • Department of Internal MedicineToyonaka Municipal Hospital
  • Hironori Take
    • Department of Internal MedicineToyonaka Municipal Hospital
  • Hiromichi Ishizashi
    • Department of Blood Transfusion MedicineNara Medical University
  • Yoshihiro Fujimura
    • Department of Blood Transfusion MedicineNara Medical University
  • Jun Kuyama
    • Department of Internal MedicineToyonaka Municipal Hospital
Case Report

DOI: 10.1532/IJH97.04187

Cite this article as:
Kosugi, S., Matsumoto, M., Ohtani, Y. et al. Int J Hematol (2005) 81: 433. doi:10.1532/IJH97.04187

Abstract

We describe a 69-year-old man with refractory relapsing thrombotic thrombocytopenic purpura (TTP) successfully treated with rituximab. The patient had once been successfully treated with plasmapheresis and vincristine, but he had relapsed after a short period. Although plasmapheresis, vincristine, and splenectomy could not achieve a consistent elevation of the platelet count, rituximab administration provided sustained remission for more than 7 months. Rituximab should be considered as a therapeutic alternative for refractory TTP.

Key words

Thrombotic thrombocytopenic purpura (TTP)Rituximabvon Willebrand factor-cleaving protease (VWF-CP)Anti-ADAMTS13 autoantibody
Download to read the full article text

Copyright information

© The Japanese Society of Hematology 2005